Asthma Affecting Patents (Class 514/1.7)
-
Publication number: 20120093883Abstract: A method for treating at least one of neuro-olfactory triggered illnesses, and related conditions within a subject is provided. The method includes the steps of: a) providing a composition that includes one or more agents adapted to induce a level of anosmia/hyposmia in the subject, which level of anosmia/hyposmia is sufficient to substantially decrease olfactory sensory stimulation within the subject and a neurologic response to the stimulation that is one or both of triggering and aggravating the illness or condition; and b) applying the composition to a nasopharynx region of the subject.Type: ApplicationFiled: April 6, 2010Publication date: April 19, 2012Inventors: Joshua D. Levine, Robert A. Levine
-
Publication number: 20120082668Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.Type: ApplicationFiled: November 10, 2011Publication date: April 5, 2012Applicant: ZYMOGENETICS, INC.Inventors: Steven D. LEVIN, Mark W. RIXON, Gao Zeren
-
Publication number: 20120077732Abstract: The present invention relates to cyclic peptides, comprising alternating D- and L- amino acids and wherein the peptide possesses immunomodulatory activity. The present invention also relates to pharmaceutical compositions comprising the cyclic peptides and to methods for the treatment of disease.Type: ApplicationFiled: November 24, 2009Publication date: March 29, 2012Applicant: SYDNEY WEST AREA HEALTH SERVICEInventors: Nicholas Manolios, Veronika Judit Bender, Marina Ali
-
Publication number: 20120077733Abstract: The invention relates to polypeptides of amino acid sequence SEQ ID NO: 1 according to formula (1), the use thereof for producing a medicament, and medicaments for the treatment of diseases related to monocyte recruitment.Type: ApplicationFiled: December 8, 2011Publication date: March 29, 2012Applicant: RWTH AACEHNInventors: Christian Weber, Philipp Von Hundelshausen, Rory Koenen
-
Publication number: 20120071394Abstract: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or a fragment or variant thereof having a biological activity of CHIPS, wherein the fragment or variant retains amino acid substitutions K40E, D42V, N77H, K100R, K105R, N111 K and/or G112A relative to the wildtype CHIPS protein of SEQ ID NO:1. In one embodiment, polypeptide consists of the amino acid sequence of SEQ ID NO: 2. Related aspects of the invention provide pharmaceutical compositions comprising a polypeptide of the invention, together with methods or making and using the same.Type: ApplicationFiled: November 30, 2009Publication date: March 22, 2012Inventors: Christina Furebring, Anna Rosén, Karin Haraldsson, Erika Gustafsson, Björn Ulrik Walse
-
Publication number: 20120071395Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: ApplicationFiled: November 23, 2011Publication date: March 22, 2012Inventor: Ira Sanders
-
Patent number: 8138141Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: July 1, 2009Date of Patent: March 20, 2012Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Publication number: 20120060834Abstract: The present invention application relates to a pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, comprising a peptide which acts on formyl peptide receptors (FPRs) or receptors analogous thereto, in an amount which is effective in suppressing respiratory inflammation. The present invention application also relates to a method for treating or preventing inflammatory respiratory diseases by using the preparation, and to a kit containing the preparation. As compared with systemic administration of the peptide by injection, direct administration of the peptide to respiratory organs remarkedly improves the effect in suppressing respiratory inflammation.Type: ApplicationFiled: May 12, 2010Publication date: March 15, 2012Applicant: Postech Academy-Industry FoundationInventors: Yoon Keun Kim, Yong Song Gho
-
Patent number: 8124734Abstract: This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.Type: GrantFiled: April 15, 2011Date of Patent: February 28, 2012Assignee: Oscient Pharmaceuticals CorporationInventors: Tim Keith, Randall Little, Paul Van Eerdewegh, Josèe Dupuis, Richard Del Mastro, Jason Simon, Kristina Allen, Sunil Pandit
-
Publication number: 20120045462Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.Type: ApplicationFiled: July 16, 2011Publication date: February 23, 2012Inventor: Thomas LUGER
-
Publication number: 20120046217Abstract: The present invention relates to: TNF-? antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-? antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-? overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.Type: ApplicationFiled: June 30, 2009Publication date: February 23, 2012Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATIONInventors: Je-Ho Lee, Jae-Ryoung Hwang, Jae-Ho Huh
-
Publication number: 20120040886Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventor: Zheng Xin Dong
-
Publication number: 20120040885Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Publication number: 20120028880Abstract: The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly D(LPR), that selectively target VEGFR-I and NRP-I expressing cells. Targeted molecules in accor-dance with the invention are useful in the treatment and detection of neovascular or angiogenic VEGF associated disorders, including but not limited to cancer, obesity, diabetes, asthma, arthritis, cirrhosis and ocular diseases.Type: ApplicationFiled: August 8, 2008Publication date: February 2, 2012Inventors: Renata Pasqualini, Wadih Arap, Ricardo Giordano, Marina Cardó-Vila, Ana Paula Valente, Fabio Ceneviva Lacerda De Almeida
-
Patent number: 8105571Abstract: A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF), mixed connective tissue disease and asthma, comprising administering an aerosolized interferon such as interferon ? in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) alone or in combination with other therapeutic agents are provided.Type: GrantFiled: July 17, 2009Date of Patent: January 31, 2012Assignees: New York University, The Research Foundation of the State University of New YorkInventors: Gerald Smaldone, Rany Condos
-
Publication number: 20120020991Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.Type: ApplicationFiled: October 7, 2011Publication date: January 26, 2012Applicant: BioZyme, Inc.Inventors: Marcia Moss, Pei Zhou
-
Publication number: 20120021971Abstract: The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic treatment of a chronic inflammatory disorder. Further, the invention relates to a clinical food product comprising heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa.Type: ApplicationFiled: July 29, 2011Publication date: January 26, 2012Applicant: Alfa Biogene International B.V.Inventor: Julia Lax
-
Publication number: 20120014998Abstract: The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.Type: ApplicationFiled: June 7, 2011Publication date: January 19, 2012Applicant: CBIO LIMITEDInventors: DEAN JASON NAYLOR, BARBARA JANE JOHNSON, CAROLINE AMANDA DOBBIN, CHRISTOPHER BRUCE HOWARD, LINDA ALLISON WARD
-
Publication number: 20120009190Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.Type: ApplicationFiled: April 20, 2008Publication date: January 12, 2012Applicant: AMGEN INC.Inventors: Sarah L. Gaffen, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
-
Publication number: 20110311548Abstract: The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists. The invention further provides a method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist.Type: ApplicationFiled: June 17, 2011Publication date: December 22, 2011Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Heather Wasserman, Timothy L. Carlson, Thi-Sau Migone, Madhav Devalaraja
-
Publication number: 20110312872Abstract: The present invention relates to Norrin or a functional fragment thereof in the treatment or prevention of diseases associated with an increased TGF-beta activity. In particular, the use of said Norrin or functional fragment thereof to treat fibrotic diseases/disorders or proliferative disorders, like cancers, is part of this invention.Type: ApplicationFiled: December 18, 2009Publication date: December 22, 2011Inventors: Ernst Tamm, Andreas Ohlmann
-
Patent number: 8080249Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with sn elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioÊ the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroallergen. Anti-ÊgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy humanized murine monoclonal antibody, and/or Qmalizumab.Type: GrantFiled: June 30, 2006Date of Patent: December 20, 2011Inventor: Glifford G. Risk
-
Publication number: 20110305634Abstract: The present invention provides compositions and methods for treating disorders associated with epithelial tissues.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Patent number: 8076281Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.Type: GrantFiled: September 10, 2008Date of Patent: December 13, 2011Assignee: IPSEN Pharma, S.A.S.Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
-
Publication number: 20110300154Abstract: The invention provides strategies for treating and preventing airway hyperreactivity and non-allergic asthma comprising antagonizing IL-17 activity and/or production by iNKT cells. Provided herein is a method of diagnosing non-allergic asthma and airway hyperreactivity comprising neutrophils quantification in sputum.Type: ApplicationFiled: August 21, 2008Publication date: December 8, 2011Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Dale T. Umetsu, Muriel Pichavant, Rosemarie Helena DeKruyff-Umetsu, Everett Hurteau Meyer, Stephanie Ann Shore
-
Patent number: 8071097Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: GrantFiled: March 21, 2008Date of Patent: December 6, 2011Assignee: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Publication number: 20110293727Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.Type: ApplicationFiled: April 8, 2011Publication date: December 1, 2011Inventors: Miguel de los Rios, John Mendlein, Timothy L. Bullock, Kenneth J. Oh, Patrick T. Johnson, Jacek Ostrowski, Stephanie de los Rios
-
Publication number: 20110288004Abstract: The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.Type: ApplicationFiled: June 21, 2007Publication date: November 24, 2011Inventors: D. Grant McFadden, Alexandra R. Lucas, John W. Barrett
-
Publication number: 20110287040Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.Type: ApplicationFiled: May 23, 2011Publication date: November 24, 2011Inventors: Theodore E. Maione, Joseph Carozza, C. Dean Maglaris
-
Publication number: 20110274698Abstract: Follistatin-like protein (FSTL-1) is a secreted glycoprotein of unknown function, first isolated from mouse osteoblastic cells as a transforming growth factor-?1-inducible gene. The inventors have discovered that FSTL-1 is a proinflammatory mediator. As such, the invention provides for composition and methods of using agents that bind to FSTL-1 to modulate various types of inflammation (e.g., autoimmune diseases). Inhibitors and antagonists of FSTL-1, particularly antibodies or antibody fragments, may be used to treat conditions related to inflammation, such as arthritis. In addition, the inventors have discovered that FSTL-1 has a role in the Th17 pathway. Accordingly, the invention provides for compositions and methods of using agents which bind to FSTL-1 to modulate the generation of Th17 cells. Such agents are useful for delaying development of and treating diseases associated with undesired production of Th17 cells, such as autoimmune diseases.Type: ApplicationFiled: June 8, 2011Publication date: November 10, 2011Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Raphael Hirsch, Anthony D. Marinov, David C. Wilson
-
Publication number: 20110262386Abstract: Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF-activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof.Type: ApplicationFiled: March 20, 2009Publication date: October 27, 2011Applicant: CAROLUS THERPEUTICS, INC.Inventors: Jürgen Bernhagen, Joshua Robert Schultz, Benedikt Vollrath, Alma Zernecke, Christian Weber
-
Publication number: 20110256130Abstract: Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of modulators of inflammation.Type: ApplicationFiled: December 1, 2009Publication date: October 20, 2011Inventors: Joshua Robert Schultz, Benedikt Vollrath, Court Turner
-
Publication number: 20110257077Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.Type: ApplicationFiled: April 19, 2011Publication date: October 20, 2011Applicant: IRM LLCInventors: David C. Tully, Amab K. Chatterjee, Agnes Vidal, Hank Michael James Petrassi, Zhiwei Wang, Badry Bursulaya, Glen Spraggon
-
Publication number: 20110250208Abstract: Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.Type: ApplicationFiled: December 21, 2009Publication date: October 13, 2011Inventor: Johan Frostegård
-
Publication number: 20110243923Abstract: The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7, 25-dihydroxycholesterol) (“7,25DHC”) and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) (“7HC”). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.Type: ApplicationFiled: July 12, 2009Publication date: October 6, 2011Inventors: Birgit Baumgarten, Francois Gessier, Andreas Katopodis, Richard Knochenmuss, Rocco Falchetto, Silvio Roggo, Andreas Sailer, Klaus Seuwen, Carsten Spanka, Juan Zhang, Sebastien Hannedouche, Sophie Noel, Marie-Odile Roy, Yu Chen, Charles Y. Cho, Wei Li, Weijun Shen
-
Patent number: 8029775Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.Type: GrantFiled: August 26, 2010Date of Patent: October 4, 2011Assignee: ZymoGenetics, Inc.Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
-
Publication number: 20110237497Abstract: A composition of a glucocorticoid receptor (GR) ligand, or analog thereof, and a V-ATPase inhibitor, or analog thereof. A method for administering such composition to a cell either to increase glucocorticoid transrepression activity or to increase glucocorticoid transactivation activity in the cell. Also, a method for treating a subject having an inflammatory or auto-immune disease by administering such composition.Type: ApplicationFiled: November 18, 2010Publication date: September 29, 2011Inventors: HUAQIANG ERIC XU, Yong Xu, Yuanzheng He
-
Publication number: 20110239311Abstract: The present invention relates to agonists/activators of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an augmented immune response. Furthermore, pharmaceutical compositions comprising said agonists/activators of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunosuppressants comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-activation with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunosuppressants.Type: ApplicationFiled: January 11, 2011Publication date: September 29, 2011Applicant: Medizinische Universitat InnsbruckInventors: Gottfried Baier, Natascha Hermann-Kleiter
-
Publication number: 20110236381Abstract: It is disclosed herein that blockade of inter-alpha-trypsin inhibitor (IaI) prevents the development of airway hyperresponsiveness in animal models of asthma and chronic obstructive pulmonary disease. Provided herein are methods of treating an airway disease or disorder in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. Also provided is a method of preventing or reducing airway hyperresponsiveness in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. The IaI inhibitor can be any compound that inhibits the expression or activity of IaI or a gene encoding an IaI polypeptide. In some embodiments, the IaI inhibitor is administered locally to the airway of the subject in need of treatment. For example, the inhibitor can be administered by aerosol delivery, such as by using an inhaler or nebulizer.Type: ApplicationFiled: April 1, 2009Publication date: September 29, 2011Inventors: Stavros Garantziotis, Yow-Pin Lim, John W. Hollingsworth, W. Michael Foster
-
Publication number: 20110236367Abstract: The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present invention is a crystal of a dipeptidyl peptidase I (DPPI) and corresponding structural information obtained by X-ray crystallography from rat and human DPPI. In addition, this invention relates to methods for using structure co-ordinates of DDPI, mutants hereof and co-complexes, to design compounds that bind to the active site or accessory binding sites of DPPI and to design improved inhibitors of DPPI or homologues of the enzyme.Type: ApplicationFiled: May 20, 2010Publication date: September 29, 2011Applicant: TeleNav, Inc.Inventors: Johan Gotthardt OLSEN, Anders Kadziola, Søren Weis Dahl, Connie Lauritzen, Sine Larsen, John Pedersen, Dusan Turk, Marjetka Podobnik, Igor Stern
-
Publication number: 20110237498Abstract: The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament, comprising an extracellular domain of SIRP? (CD172a) or functional derivatives which bind to human CD47.Type: ApplicationFiled: December 17, 2009Publication date: September 29, 2011Applicant: NOVARTIS AGInventors: Marianne Raymond, Marie Sarfati, Karl Welzenbach, Maximilian Woisetschlaeger
-
Publication number: 20110212884Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: ApplicationFiled: April 20, 2010Publication date: September 1, 2011Applicant: Synergy Pharmaceuticals, Inc.Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Publication number: 20110207655Abstract: [Problem]A compound useful for the prevention and/or treatment of chronic obstructive pulmonary disease (COPD) or asthma, and a pharmaceutical composition containing the compound as an active ingredient are provided. [Means for Solution]The present inventors have made extensive studies on the pharmacological actions of naturally fermented materials, and as a result, they have found that a cyclic depsipeptide compound derived from a soil bacterium belonging to the genus Chromobacterium which is collected in Okutama-machi, Tokyo has both an inhibitory action on airway contraction and an inhibitory action on airway inflammation, and thus, is useful as an agent for preventing or treating COPD or asthma, thereby completing the present invention.Type: ApplicationFiled: October 23, 2009Publication date: August 25, 2011Applicant: Astellas Pharma Inc.Inventors: Susumu Tsujimoto, Masatoshi Taniguchi, Yoshitaka Hirayama, Jun Takasaki, Tomihisa Kawasaki, Kazutoshi Sakamoto, Shinya Nishiwaki, Yukihiro Kitanaga
-
Publication number: 20110190195Abstract: An antioxidant compound is disclosed.Type: ApplicationFiled: April 14, 2011Publication date: August 4, 2011Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Daphne ATLAS
-
Publication number: 20110183886Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: March 29, 2011Publication date: July 28, 2011Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
-
Publication number: 20110183889Abstract: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide.Type: ApplicationFiled: August 28, 2008Publication date: July 28, 2011Applicant: The Regents of the University of CaliforniaInventors: Alan M. Fogelman, Mohamad Navab
-
Publication number: 20110177065Abstract: The invention relates to the combined use of an IL-1 antagonist/inhibitor and IL-18 binding protein in inflammatory diseases.Type: ApplicationFiled: February 15, 2011Publication date: July 21, 2011Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Menachem Rubinstein, Daniela Novick, Vladimir Hurgin
-
Publication number: 20110177998Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: July 11, 2008Publication date: July 21, 2011Inventors: Ronen Shemesh, Zurit Levine, Amir Toporik, Chen Hermesh, Yossef Kliger, Eyal Gofer, Assaf Wool, Dvir Dahary, Yossi Cohen
-
Publication number: 20110160119Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: ApplicationFiled: December 2, 2010Publication date: June 30, 2011Applicant: YALE UNIVERSITYInventors: Michael J. May, Sankar Ghosh
-
Publication number: 20110160120Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.Type: ApplicationFiled: January 20, 2011Publication date: June 30, 2011Applicant: Synergy Pharmaceuticals Inc.Inventors: Kunwar Shailubhai, Gary S. Jacob